Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder in which the immune system attacks the protective covering of peripheral nerves. This inflammation can interfere with nerve signals and cause progressive weakness, numbness, tingling, and problems with balance or walking. Although CIDP can be a long-term condition, treatment can reduce inflammation, improve nerve function, and help prevent further disability. Early diagnosis, individualized treatment, and regular monitoring by a neurological care team are important components of long-term CIDP management.
CIDP affects the peripheral nerves that connect the brain and spinal cord with the muscles and sensory organs.
The immune system damages the myelin sheath, the protective layer surrounding many nerves. This slows or disrupts nerve signals.
CIDP may develop gradually over several weeks or months and can cause symptoms on both sides of the body.
Symptoms vary among individuals but may include:
Symptoms may worsen gradually or occur in periods of relapse and improvement.
There is no single test that confirms CIDP. Diagnosis usually involves neurological examination and specialized testing.
Healthcare providers may recommend:
Accurate diagnosis is important because several neurological disorders can produce similar symptoms.
Treatment aims to reduce the abnormal immune response and improve nerve function.
Common treatment approaches include:
Treatment is individualized based on symptom severity, response to therapy, other medical conditions, and whether relapses occur.
IVIG is commonly used to treat CIDP. It contains antibodies collected from donated plasma and can help modify the abnormal immune response affecting peripheral nerves.
Some individuals require repeated infusions to maintain improvement.
Corticosteroids can reduce inflammation and may improve strength and neurological function in some individuals.
When standard therapies are insufficient or poorly tolerated, specialists may consider other immune-modulating medications. Treatment selection depends on the individual's disease characteristics and response.
Plasma exchange, also called plasmapheresis, removes plasma containing certain immune components from the bloodstream and replaces it with another fluid.
It may provide improvement for some people with CIDP, particularly when rapid treatment is needed or other therapies have not produced adequate results.
Rehabilitation can help maintain strength, mobility, and independence.
Physical therapy may focus on:
Occupational therapy can help with everyday activities and recommend adaptive equipment when necessary.
Regular follow-up is important because CIDP can change over time.
Monitoring may include:
Treatment may be adjusted when symptoms improve, worsen, or return after a period of stability.
Prompt medical evaluation is recommended if there is:
Severe or rapidly progressive symptoms may require urgent assessment.
CIDP is a treatable condition, although some individuals require long-term therapy. Responses to treatment vary, and periods of remission or relapse may occur.
Early diagnosis and appropriate treatment can help reduce nerve damage and improve mobility and daily functioning. Regular neurological follow-up allows treatment to be adjusted according to disease activity.
Chronic inflammatory demyelinating polyneuropathy is an immune-related neurological disorder that can cause progressive weakness, sensory changes, and mobility problems. Treatments such as IVIG, corticosteroids, plasma exchange, and selected immune-modulating therapies can help control the disease and improve nerve function. Physical and occupational therapy can further support mobility and independence.